Respiratory
The management of 
respiratory disease remains an important healthcare challenge. Within the respiratory disease therapeutic area, AstraZeneca focuses on asthma treatment offering a complete and comprehensive approach to the management of this disease area
AstraZeneca provides a wide range of innovative products and inhalation devices that are designed to optimise the treatment of asthma. Among other products, the company markets Symbicord®, Bricanyl®, Oxis®, Pulmicort®and Accolate®.
Symbicord® is a novel asthma treatment consisting of the inhaled corticosteroid budesonide in combination with the fast and long-acting beta2 agonist formoterol [1] in the world's most widely sold powder inhaler - the Turbuhaler [2].
Bricanyl® (terbutaline sulphate) is a short-acting beta agonist [3].
Oxis® (formoterol) is a long-acting beta2 agonist [4].
Pulmicort® (budesonide) is an inhaled corticosteroid [5]. It is available in a range of different technologies, including nebulising suspension[5], and a dry powder device called the Turbuhaler®. The Turbuhaler® has been shown to deliver more product to the lungs than any other dry powder inhalation device on the market [7].
Accolate® (zafirlukast) is a leukotriene receptor antagonist [6].
AstraZeneca's superb range of products for the treatment of respiratory disease allows the doctor who is treating the asthmatic many more options, and, because of its comprehensive range of treatments, the company is able to promote sound evidence-based medicine according to the stepwise treatment guidelines.
For more information for your patients and their families please use the links below:
Patienthealth.com, NewToAsthma.com, AsthmaAndPregnancy.com, AsthmaAndChildren.com, site for children Bubbliboo.com.
and for Physicians www.AZ-Air.com
By following these links you are leaving this site to visit another AstraZeneca which may be intended for certain audiences and countries only.
